Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks Breaking Out

By Dave Mock - Updated Apr 6, 2017 at 12:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sorting a real growth story from a flash in the pan

Volatile markets seem to be the norm these days, as stocks gyrate through ups and downs on a daily basis. But sometimes buyout news and other short-term forces can send individual stocks soaring by 10%, 25%, even 50% -- even on the market's worst days.   

For example, shares of Playboy Enterprises jumped 41% after owner Hugh Hefner offered to buy out the shares he doesn't already own.

But beyond less-predictable events like that one are stocks with fundamentally compelling reasons behind a big move. The trick is to find those stocks. That's where Motley Fool CAPS comes in.

The story behind the story
CAPS is no crowd of lemmings. Its best-performing members' opinions do more to shape each company's rating than the picks of their poorer-performing peers. Here's an example of how we can use the collective wisdom of more than 165,000 CAPS members to filter out the noise and find companies with strong potential.

We'll use CAPS' handy stock screening tool to quickly zero in on companies with a stock price increase of at least 15% in the past four weeks, a market cap of greater than $100 million, and a beta of less than 3. Then we can use the insight of the CAPS investment community to add some context to these market movers.

Company

CAPS Rating
(out of 5)

4-Week
Price Change

CF Industries (NYSE: CF)

****

19.8%

Biovail (NYSE: BVF)

***

40.3%

IDT (NYSE: IDT)

**

44.2%

Source: Motley Fool CAPS. Price return from June 18 through July 16.

CF Industries
Fertilizer producer Agrium (NYSE: AGU) has been talking turnaround following its first-quarter loss, and peer CF's shares have recently reversed course thanks to some positive signs in the industry as well. A U.S. report recently showed smaller than expected inventories from 2009's corn crop and Norwegian Yara International posted bullish second quarter results helped by higher global nitrogen prices. Many CAPS members like CF Industries' improved position following its acquisition of Terra Industries and like the long-term outlook for fertilizer demand as 96% of the 1,115 CAPS members rating CF Industries expect it to beat the broader market.

Biovail
Specialty pharmaceutical company Biovail reported a 28% jump in first-quarter revenue, helped by strength in one of its key revenue drivers Wellbutrin XL, for which it acquired commercialization rights from GlaxoSmithKline (NYSE: GSK) last year. It also saw strong sales of other products including its generics portfolio, a number of which are distributed by Teva Pharmaceutical (Nasdaq: TEVA). Despite a quarterly loss, many investors have remained more focused on the potential in its recently announced merger with Valeant Pharmaceuticals, which sent shares soaring. The deal is expected to enable significant cost savings and create a much stronger player with the enhanced ability to tackle key drug markets like neurological drugs. In CAPS, 92% of the 483 members rating Biovail believe it will be a market-beating investment.  

IDT
After losing nearly all of their value by late 2008, shares of IDT have been on fire over the past year, rising more than 650%. The diversified company, with operations ranging from prepaid phone cards to reselling electricity, recently swung back to a fiscal third-quarter profit. And investors have been responding positively to the company's oil shale venture in Colorado with partner Total SA (NYSE: TOT) following an appearance on CNBC by IDT's CEO. Not all CAPS members see the stock as a good play though and the community hasn't afforded the company any better than two stars for years, as only 71% of the 94 members rating IDT are bullish on its chances to outperform the S&P.

And you?
What's your story? Whether you buy the tale of a stock that's soaring or souring, your own research is more important than collective opinions. But these collective opinions can make your due diligence a whole lot easier.

Add your take on these or any of the 5,400 stocks that our 165,000-plus members have covered in Motley Fool CAPS. It's totally free to be a part of the community, and the payback is more than worth it.

The Motley Fool Stock Advisor service looks for companies with strong management poised to beat the market over the long haul. To see all the stocks that have helped Tom and David Gardner beat the market by 60 points on average, take a free 30-day trial.

Fool contributor Dave Mock has his own story, but there's no "happily ever after" at the end of it. He owns no shares of companies mentioned here. Total S.A. is an Income Investor choice. The Fool owns shares of GlaxoSmithKline. The Fool's disclosure policy has the momentum of a freight train, but can stop on a dime.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TotalEnergies Stock Quote
TotalEnergies
TTE
$50.68 (2.01%) $1.00
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$10.99 (2.85%) $0.30
GSK Stock Quote
GSK
GSK
$40.33 (-0.60%) $0.24
CF Industries Holdings, Inc. Stock Quote
CF Industries Holdings, Inc.
CF
$99.50 (-0.55%) $0.55
IDT Corporation Stock Quote
IDT Corporation
IDT
$27.17 (1.15%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.